HONG KONG – Aiming to expand its market in greater China, Cstone Pharmaceuticals Co. Ltd. submitted a new drug application (NDA) for Tibsovo (ivosidenib) to the Taiwan Food and Drug Administration (TFDA), seeking approval of the first drug to treat adults with relapsed or refractory (r/r) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.